Sacituzumab govitecan for metastatic breast cancer: the TROPiCS-02 trial

被引：0
|
作者：
Ergun, Yakup [1 ]
机构：
[1] Antalya City Hosp, Dept Med Oncol, TR-07080 Antalya, Turkiye
来源：
LANCET | 2024年 / 404卷 / 10450期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
下载
收藏
页码：337 / 338
页数：2
相关论文
共 50 条
  • [1] TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2-metastatic breast cancer
    Rugo, Hope S.
    Bardia, Aditya
    Tolaney, Sara M.
    Arteaga, Carlos
    Cortes, Javier
    Sohn, Joohyuk
    Marme, Frederik
    Hong, Quan
    Delaney, Rosemary J.
    Hafeez, Amir
    Andre, Fabrice
    Schmid, Peter
    FUTURE ONCOLOGY, 2020, 16 (12) : 705 - 715
  • [2] Health-related quality of life with sacituzumab govitecan in HR+/HER2-metastatic breast cancer in the phase III TROPiCS-02 trial
    Rugo, Hope S.
    Schmid, Peter
    Tolaney, Sara M.
    Dalenc, Florence
    Marme, Frederik
    Shi, Ling
    Verret, Wendy
    Shah, Anuj
    Gharaibeh, Mahdi
    Bardia, Aditya
    Cortes, Javier
    ONCOLOGIST, 2024, 29 (09): : 768 - 779
  • [3] Effect of sacituzumab govitecan vs chemotherapy in HR+/HER2-metastatic breast cancer: patient-reported outcomes from the TROPiCS-02 trial
    Marme, Frederik
    Bardia, Aditya
    Rugo, Hope
    Schmid, Peter
    Tolaney, Sara M.
    Oliveira, Mafalda
    Schneeweiss, Andreas
    Shi, Ling
    Verret, Wendy
    Gharaibeh, Mahdi
    Shah, Anju
    Cortes, Javier
    CANCER RESEARCH, 2023, 83 (05)
  • [4] Sacituzumab Govitecan in Metastatic Breast Cancer
    Ganguly, Shuvadeep
    Gogia, Ajay
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (03):
  • [5] Sacituzumab-govitecan in metastatic breast cancer
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2023, 83 (01)
  • [6] Health-related quality of life (HRQoL) in the phase III TROPiCS-02 trial of sacituzumab govitecan (SG) vs chemotherapy in HR+/HER2-metastatic breast cancer (MBC)
    Rugo, H. S.
    Schmid, P.
    Tolaney, S. M.
    Dalenc, F.
    Marme, F.
    Shi, L.
    Verret, W.
    Gharaibeh, M.
    Bardia, A.
    Cortes, J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1258 - S1258
  • [7] Sacituzumab Govitecan in Metastatic Breast Cancer REPLY
    Bardia, Aditya
    Hurvitz, Sara A.
    Rugo, Hope S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (03):
  • [8] Safety outcomes by UGT1A1 status in the phase III TROPiCS-02 study of sacituzumab govitecan (SG) in HR+/HER2-metastatic breast cancer (mBC)
    Heong, V. Y. M.
    Marme, F.
    Rugo, H. S.
    Tolaney, S. M.
    Bardia, A.
    Schmid, P.
    Verret, W.
    Valdez, T.
    Wang, H.
    Cortes, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S1486 - S1487
  • [9] Clinical Outcomes by Age Subgroups in the Phase 3 TROPiCS-02 Study of Sacituzumab Govitecan vs Treatment of Physician's Choice in HR+/ HER2- Metastatic Breast Cancer
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2024, 22 (01)
  • [10] Sacituzumab Govitecan vs Treatment of Physician's Choice: Efficacy by Trop-2 Expression in the TROPiCS-02 Study of Patients With HR+/ HER2- Metastatic Breast Cancer
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (02) : 5 - 6
12345